T h e W o r k : P rofessional A dvertising 1. AGENCY: Surge Worldwide CREATIVE TEAM: Rick Beardsley, John Sarno, Paul Weiss CLIENT: Shire 2. AGENCY: DraftFCB Healthcare CREATIVE TEAM: Alan Rothenberg, John Fallon CLIENT: Amgen 3. AGENCY: AbelsonTaylor CREATIVE TEAM: Janet Kleve, Mark Wasserman, Jan Podjasek, Donna Arey, Caren Spigland, Jonathan Davila, Tim Brennan, Lauren Cunningham CLIENT: Astellas K in d e r to kid neys AmBisome delivers the power of amphotericin B with significantly lower nephrotoxicity than Abelcet. • Proven power'a - Power for empiric therapy in febrile neutropenic patients with presumed fungal infections - Power against breakthrough infections in empiric therapy Superior safety versus Abefcet” -2/3 less nephrotoxicity -Significantly fewer discontinuations and infusion-related reactions AmBisome is indicated for the following: • Empirical therapy for presumed fungal infection in febrile neutropenic patients ♦ Treatment of Cryptococcal Meningitis in HIV-infected patients * Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate • Treatment of visceral leishmaniasis; in immunocompromised patients with visceral leishmaniasis treated with AmBisome, relapse rates were high following initial clearance or parasites Important Safety Information Dose-limiting renal toxicity may still be observed with AmBisome even though significantly less nephrotoxicity was observed at dosages of 3 mg/kg/day and 5 mg/kg/day compared to Abelcet at a dosage of 5 mg/kg/day. The toxicity of AmBisome due to overdose has not been defined. Repeated daily doses up to 10 mg/kg m pediatric patients and 15 mg/kg in adult patients have been administered in clinical trials with no reported dose-related toxicity. There have been a few reports of flushing, back pain with or without chest tightness, and chest pain associated with AmBisome administration; on occasion this has been severe. Anaphylaxis has been reported with amphotericin B formulations including AmBisome. Abelcet* b a registered tractemaik of Enron Pteimaceuticate. I Please see adjacent brief summary of full prescribing information. AmBisome | (amhpotericBin)liposomefoirnjenctio Fierce on fungus. Kinder to kidneys. (Jj GILEAO 219
RkJQdWJsaXNoZXIy NDMwNDAx